Responses
Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
312 Three-year outcomes with first-line pembrolizumab for metastatic non–small-cell lung cancer (NSCLC) with a very high PD-L1 tumor proportion score (TPS) ≥ 90%
Compose a Response to This Article
Other responses
No responses have been published for this article.